Ken Griffin Trevena Inc Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$0.2 - $0.5 $85,046 - $212,616
425,233 Added 724.15%
483,955 $200,000
Q1 2022

May 16, 2022
SELL
$0.41 - $0.63 $40,669 - $62,492
-99,194 Reduced 62.81%
58,722 $32,000
Q4 2021

Feb 14, 2022
BUY
$0.57 - $1.29 $72,467 - $164,005
127,136 Added 413.05%
157,916 $91,000
Q3 2021

Nov 15, 2021
SELL
$1.11 - $1.7 $118,427 - $181,374
-106,691 Reduced 77.61%
30,780 $38,000
Q2 2021

Aug 16, 2021
SELL
$1.46 - $2.25 $837,242 - $1.29 Million
-573,454 Reduced 80.66%
137,471 $232,000
Q1 2021

May 17, 2021
BUY
$1.77 - $2.93 $1.22 Million - $2.03 Million
692,007 Added 3657.93%
710,925 $1.27 Million
Q3 2020

Nov 16, 2020
SELL
$1.53 - $3.13 $517,964 - $1.06 Million
-338,539 Reduced 94.71%
18,918 $57,000
Q2 2020

Aug 14, 2020
BUY
$0.48 - $1.75 $108,726 - $396,397
226,513 Added 172.98%
357,457 $536,000
Q1 2020

May 15, 2020
BUY
$0.56 - $0.97 $73,328 - $127,015
130,944 New
130,944 $74,000
Q4 2019

Feb 14, 2020
SELL
$0.62 - $1.06 $7,980 - $13,644
-12,872 Closed
0 $0
Q3 2019

Nov 14, 2019
SELL
$0.81 - $1.06 $79,525 - $104,070
-98,180 Reduced 88.41%
12,872 $12,000
Q2 2019

Aug 14, 2019
BUY
$0.94 - $1.6 $85,113 - $144,873
90,546 Added 441.56%
111,052 $114,000
Q1 2019

May 15, 2019
SELL
$0.51 - $1.88 $41,934 - $154,583
-82,225 Reduced 80.04%
20,506 $0
Q4 2018

Feb 14, 2019
BUY
$0.39 - $3.47 $27,161 - $241,664
69,644 Added 210.49%
102,731 $44,000
Q3 2018

Nov 13, 2018
BUY
$1.39 - $2.25 $25,564 - $41,382
18,392 Added 125.16%
33,087 $0
Q1 2018

May 11, 2018
BUY
$1.51 - $2.06 $6,058 - $8,264
4,012 Added 37.55%
14,695 $24,000
Q4 2017

Feb 09, 2018
BUY
$1.4 - $2.6 $14,956 - $27,775
10,683
10,683 $17,000

About TREVENA INC

TRVN Quotes by TradingView
  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $273M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email